Neurothera Labs Inc.
NTLX.V
TSX
| 09/30/2025 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 236.00K | 260.00K | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 236.00K | 260.00K | |||
| Cost of Revenue | 70.00K | 91.00K | |||
| Gross Profit | 166.00K | 169.00K | |||
| SG&A Expenses | 260.00K | 338.00K | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 330.00K | 429.00K | |||
| Operating Income | -94.00K | -169.00K | |||
| Income Before Tax | -94.00K | -169.00K | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -94.00K | -169.00K | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -94.00K | -169.00K | |||
| EBIT | -94.00K | -169.00K | |||
| EBITDA | -46.00K | -77.30K | |||
| EPS Basic | -- | -- | |||
| Normalized Basic EPS | -- | -- | |||
| EPS Diluted | -- | -- | |||
| Normalized Diluted EPS | -- | -- | |||
| Average Basic Shares Outstanding | -- | -- | |||
| Average Diluted Shares Outstanding | -- | -- | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||